Skip to main content
Barbara E. F. Pregler on Muck Rack

Barbara E. F. Pregler

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara E. F.

Contact Barbara E. F., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial

|
By Frank A. Giordano, Julian P. Layer, Roberta Turiello, Lea L. Friker, Oriol Mirallas, Anna-Laura Potthoff, Thomas Zeyen, Johannes Weller, Elena Sperk, Katharina Sahm, Christoph Oster, Sied Kebir, Niklas Schäfer, Sebastian Kadzik, Mirjam Renovanz, Torsten Pietsch, Sotirios Bisdas, Juan Manuel Sepúlveda-Sánchez, Diego Gómez-Puerto, Maria Vieito, Michael Platten, Eleni Gkika, Oliver M. Grauer, Ghazaleh Tabatabai, Matthias Schneider, Martin Glas Verified, Clemens Seidel, Ulrich Herrlinger, Michael Hölzel, Barbara E. F. Pregler, Peter Hambsch
| Nature Verified
Abstract Rapid vascular recovery is a key feature preceding glioblastoma (GBM) recurrence after radiotherapy (RT). We performed spatial expression analyses, providing a rationale for dual inhibition of two non-redundant, spatially distinct acting factors, CXCL12 and VEGF.
Open in Who Shared Issue with article?
See all 1 articles